Cargando…
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
There have been significant advances with regard to BRAF-targeted therapies against metastatic melanoma. However, the majority of patients receiving BRAF inhibitors (BRAFi) manifest disease progression within a year. We have recently shown that melanoma patients treated with BRAFi exhibit an increas...
Autores principales: | Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827093/ https://www.ncbi.nlm.nih.gov/pubmed/24251082 http://dx.doi.org/10.4161/onci.26615 |
Ejemplares similares
-
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
por: Friedman, Adam A., et al.
Publicado: (2015) -
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013) -
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
por: Sabbatino, Francesco, et al.
Publicado: (2014) -
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
por: Shen, Che-Hung, et al.
Publicado: (2016) -
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
por: Kim, Hyungsoo, et al.
Publicado: (2015)